In this Pharmaceutical Executive video interview, Murray Aitken, Executive Director of the IQVIA Institute for Human Data Science, discusses why no novel active substances have yet been brought to market through AI technology despite increasing investments in the space for drug discovery as shown in IQVIA’s Global Trends in R&D 2024 report.
Hurdles Hindering the Translation of AI-Powered Research into Tangible Clinical Benefits
![](https://onclive.s3.amazonaws.com/onclive_630x1200.png)
Estimated read time
1 min read
+ There are no comments
Add yours